GSK Launches ReQuip XL(R) (ropinirole Prolonged-release Tablets) A New Once Daily Formulation For The Treatment Of Parkinson's Disease
Article Date: 19 May 2008 - 1:00 PDT
GlaxoSmithKline (GSK) have announced the launch of a new treatment for Parkinson's disease (PD) in the UK. ReQuip XL® (ropinirole prolonged-release tablets) is the UK's first and only once-daily non-ergot oral dopamine agonist available for the treatment of PD1, providing continuous delivery of ropinirole from a single daily dose2.
Ropinirole prolonged-release is approved for the treatment of idiopathic Parkinson's disease (Monotherapy and Adjunct Therapy) in patients already taking ropinirole immediate release tablets and in whom adequate symptomatic control has been established1.
READ more...